Health & Biotech
Headquartered in Auckland, New Zealand, Aroa Biosurgery is a soft-tissue regeneration company committed to unlocking regenerative healing for everybody through its patented AROA ECM™ complex wound and tissue reconstruction products.
The company was founded in 2008 by Veterinarian Surgeon Dr Brian Ward, who discovered that a tissue scaffold called the extra cellular matrix (ECM) found in the forestomach of sheep has a similar structure to human tissue and contains over 150 proteins known to be important in the healing process.
Listed on the ASX since 2020, Aroa Biosurgery has established USA operations, regulatory approval in over 50 countries and employs over 270 people in New Zealand and North America.
Over 6 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. www.aroabio.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
IPO Watch
IPO Watch: Doctor Care Anywhere set to join the ASX telehealth ranks next month
News
Charted: Why fund managers have their eye on these ASX small caps
IPO Watch
The driving forces behind Australia’s red-hot IPO market
News
ASX gold, New Zealand-headquartered small caps take a hit; investors told not to panic
Health & Biotech
Check up: Maybe next week will be better?
News
ASX capital raisings top $30b in 2020 so far
Health & Biotech
Shares in new IPO Aroa Biosurgery have now doubled in a week
IPO Watch